Ramon Alemany

Summary

Country: Spain

Publications

  1. doi request reprint Viruses in cancer treatment
    R Alemany
    Catalan Institute of Oncology, Bellvitge Institute of Research, Barcelona, Spain
    Clin Transl Oncol 15:182-8. 2013
  2. doi request reprint Chapter four--Design of improved oncolytic adenoviruses
    Ramon Alemany
    Translational Research Laboratory, Institut Català d Oncologia IDIBELL, L Hospitalet de Llobregat, Barcelona, Spain
    Adv Cancer Res 115:93-114. 2012
  3. doi request reprint Oncolytic viruses from the perspective of the immune system
    Ramon Alemany
    Institut Català d Oncologia ICO, Av Gran Via s n Km 2, 7, L Hospitalet de Llobregat, 08907 Barcelona, Spain
    Future Microbiol 4:527-36. 2009
  4. doi request reprint Positive selection of gene-modified cells increases the efficacy of pancreatic cancer suicide gene therapy
    Jordi Martinez-Quintanilla
    Gene and Viral Therapy Group, IDIBELL Catalan Institute of Oncology ICO, L Hospitalet de Llobregat, UPF, Parc de Recerca Biomédica de Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Raras CIBERER ISCIII, Barcelona, Spain
    Mol Cancer Ther 8:3098-107. 2009
  5. pmc Intraductal delivery of adenoviruses targets pancreatic tumors in transgenic Ela-myc mice and orthotopic xenografts
    Anabel José
    Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Barcelona, Spain
    Oncotarget 4:94-105. 2013
  6. pmc Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses
    Juan J Rojas
    Translational Research Laboratory, IDIBELL Institut Català d Oncologia, L Hospitalet de Llobregat, Barcelona, Spain
    Mol Ther 18:1960-71. 2010
  7. doi request reprint Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting
    Neus Bayo-Puxan
    Translational Research Laboratory, Institut d Investigació Biomèdica de Bellvitge IDIBELL Institut Català d Oncologia, L Hospitalet de Llobregat, 08907 Barcelona, Spain
    Hum Gene Ther 20:1214-21. 2009
  8. pmc Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses
    Alena Gros
    Translational Research Laboratory, IDIBELL Institut Català d Oncologia, L Hospitalet de Llobregat, Barcelona, Spain
    Mol Ther 18:903-11. 2010
  9. pmc Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models
    Meritxell Huch
    Programa Gens i Malaltia, Centre de Regulacio Genomica CRG, UPF, Parc de Recerca Biomédica de Barcelona PRBB, Barcelona, Spain
    Neoplasia 11:518-28, 4 p following 528. 2009
  10. ncbi request reprint Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway
    Manel Cascallo
    Translational Research Laboratory, Institut d Investigació Biomèdica de Bellvitge Institut Català d Oncologia, L Hospitalet de Llobregat, Barcelona, Spain
    Mol Ther 15:1607-15. 2007

Collaborators

  • Cristina Fillat
  • Miguel Chillon
  • David G Mollevi
  • Juan Fueyo
  • Marta M Alonso
  • Manel Cascallo
  • Alena Gros
  • Jordi Martinez-Quintanilla
  • Marta Gimenez-Alejandre
  • Sonia Guedan
  • Neus Bayo-Puxan
  • Meritxell Huch
  • Anabel José
  • Juan J Rojas
  • Cristina Puig-Saus
  • Nuria Andreu
  • Daniel Abate-Daga
  • Juan José Rojas
  • Cristina Puig
  • Juan Miguel Camacho-Sánchez
  • Luciano Sobrevals
  • Eduard Ayuso
  • Pilar Navarro
  • Juan Camacho-Sánchez
  • Olga Millán
  • Raul Herance
  • Peter F Searle
  • Francisca Alcayaga-Miranda
  • Raúl Gil-Hoyos
  • Elena Mercade
  • Sergio Lavilla-Alonso
  • Akseli Hemminki
  • Juan Ramon Gonzalez
  • Anna Perez-Gimenez
  • Teresa Serrano
  • Gabriel Capella
  • Neus Bayo

Detail Information

Publications23

  1. doi request reprint Viruses in cancer treatment
    R Alemany
    Catalan Institute of Oncology, Bellvitge Institute of Research, Barcelona, Spain
    Clin Transl Oncol 15:182-8. 2013
    ..Virotherapy history, viruses, considerations for clinical trials, and hurdles are briefly overviewed...
  2. doi request reprint Chapter four--Design of improved oncolytic adenoviruses
    Ramon Alemany
    Translational Research Laboratory, Institut Català d Oncologia IDIBELL, L Hospitalet de Llobregat, Barcelona, Spain
    Adv Cancer Res 115:93-114. 2012
    ....
  3. doi request reprint Oncolytic viruses from the perspective of the immune system
    Ramon Alemany
    Institut Català d Oncologia ICO, Av Gran Via s n Km 2, 7, L Hospitalet de Llobregat, 08907 Barcelona, Spain
    Future Microbiol 4:527-36. 2009
    ..What seems clear is that at this intersection one should take one route or the other to overcome the current limitations of virotherapy...
  4. doi request reprint Positive selection of gene-modified cells increases the efficacy of pancreatic cancer suicide gene therapy
    Jordi Martinez-Quintanilla
    Gene and Viral Therapy Group, IDIBELL Catalan Institute of Oncology ICO, L Hospitalet de Llobregat, UPF, Parc de Recerca Biomédica de Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Raras CIBERER ISCIII, Barcelona, Spain
    Mol Cancer Ther 8:3098-107. 2009
    ....
  5. pmc Intraductal delivery of adenoviruses targets pancreatic tumors in transgenic Ela-myc mice and orthotopic xenografts
    Anabel José
    Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Barcelona, Spain
    Oncotarget 4:94-105. 2013
    ..In summary our data show that cytotoxic adenoviruses retrogradelly injected to the pancreas can be a feasible approach to treat localized pancreatic tumors...
  6. pmc Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses
    Juan J Rojas
    Translational Research Laboratory, IDIBELL Institut Català d Oncologia, L Hospitalet de Llobregat, Barcelona, Spain
    Mol Ther 18:1960-71. 2010
    ..Furthermore, the constrained genome size of this backbone allows an efficient and potent expression of transgenes, indicating that this virus holds promise for overcoming the limitations of oncolytic adenoviral therapy...
  7. doi request reprint Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting
    Neus Bayo-Puxan
    Translational Research Laboratory, Institut d Investigació Biomèdica de Bellvitge IDIBELL Institut Català d Oncologia, L Hospitalet de Llobregat, 08907 Barcelona, Spain
    Hum Gene Ther 20:1214-21. 2009
    ..Similar to RGD at the HI-loop, RGD at this new shaft location efficiently enhances the infectivity of adenovirus and improves the tumor-to-liver transduction ratio in vivo...
  8. pmc Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses
    Alena Gros
    Translational Research Laboratory, IDIBELL Institut Català d Oncologia, L Hospitalet de Llobregat, Barcelona, Spain
    Mol Ther 18:903-11. 2010
    ..Overall, our findings indicate that verapamil provides a new, safe, and versatile way to improve the antitumoral potency of oncolytic adenoviruses in the clinical setting...
  9. pmc Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models
    Meritxell Huch
    Programa Gens i Malaltia, Centre de Regulacio Genomica CRG, UPF, Parc de Recerca Biomédica de Barcelona PRBB, Barcelona, Spain
    Neoplasia 11:518-28, 4 p following 528. 2009
    ..43 x 10(-5)). The antitumoral selective activity of AduPARE1A shows the potential of uPAR promoter-based therapies in pancreatic cancer treatment...
  10. ncbi request reprint Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway
    Manel Cascallo
    Translational Research Laboratory, Institut d Investigació Biomèdica de Bellvitge Institut Català d Oncologia, L Hospitalet de Llobregat, Barcelona, Spain
    Mol Ther 15:1607-15. 2007
    ..Dose-response toxicological and efficacy studies after a single systemic administration in pre-clinical models in mice are presented to demonstrate that this virus holds promise for treatment of disseminated cancer...
  11. pmc Oncolytic adenoviruses armed with thymidine kinase can be traced by PET imaging and show potent antitumoural effects by ganciclovir dosing
    Daniel Abate-Daga
    Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Barcelona, Spain
    PLoS ONE 6:e26142. 2011
    ..Thus, TK-expressing oncolytic adenoviruses can be traced by PET imaging providing real time information on the activity of the virus and its antitumoral potency can be optimized by GCV dosing...
  12. pmc Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth
    Sonia Guedan
    Translational Research Laboratory, IDIBELL Institut Català d Oncologia, L Hospitalet de Llobregat, Barcelona, Spain
    Mol Ther 18:1275-83. 2010
    ..Importantly, a single intravenous dose of ICOVIR17 induced tumor regression in 60% of treated tumors. These results indicate that ICOVIR17 is a promising candidate for clinical testing...
  13. doi request reprint Coagulation factors determine tumor transduction in vivo
    Marta Gimenez-Alejandre
    Translational Research Laboratory, Institut d Investigació Biomèdica de Bellvitge Institut Català d Oncologia, L Hospitalet de Llobregat, 08907 Barcelona, Spain
    Hum Gene Ther 19:1415-9. 2008
    ..This finding imposes new challenges to retarget adenoviruses in vivo...
  14. doi request reprint Antitumor therapy based on cellular competition
    Jordi Martinez-Quintanilla
    Gene and Viral Therapy Group, IDIBELL Catalan Institute of Oncology ICO, L Hospitalet de Llobregat, 08907 Barcelona, Spain
    Hum Gene Ther 20:728-38. 2009
    ..1 to 90% in 35 days). After this positive selection period, negative selection with GCV eliminated the transfected cells. In vivo, positive selection was also achieved and resulted in a statistically significant therapeutic effect...
  15. doi request reprint Construction of capsid-modified adenoviruses by recombination in yeast and purification by iodixanol-gradient
    Marta Gimenez-Alejandre
    Institut Català d Oncologia IDIBELL, L Hospitalet de Llobregat, Barcelona, Spain
    Methods Mol Biol 797:21-34. 2012
    ..Moreover, viral stocks are more viable and it can be used for large-scale purifications. Finally, a protocol for analyzing blood persistence of modified vector in in vivo biodistribution is presented...
  16. ncbi request reprint Deletion of VAI and VAII RNA genes in the design of oncolytic adenoviruses
    Manel Cascallo
    Translational Research Laboratory, Institut Catala d Oncologia, L Hospitalet de Llobregat, 08907 Barcelona, Spain
    Hum Gene Ther 17:929-40. 2006
    ..The mRNA translation promoted by VA RNA genes can be phenocopied in tumor cells with the activation of signal transduction pathways, such as the Ras pathway...
  17. pmc Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers
    Cristina Puig-Saus
    Translational Research Laboratory, IDIBELL Institut Català d Oncologia, L Hospitalet de Llobregat, Barcelona, Spain
    Mol Ther 20:54-62. 2012
    ..These results indicate that the i-leader truncation represents a promising trait to improve virotherapy with oncolytic adenoviruses...
  18. ncbi request reprint Designing adenoviral vectors for tumor-specific targeting
    Ramon Alemany
    Translational Research Laboratory, Catalan Institute of Oncology, L Hospitalet de Llobregat, Barcelona, Spain
    Methods Mol Biol 542:57-74. 2009
    ..Finally, mutations and transgenes that can enhance the potency and efficacy of tumor-targeted adenoviruses from virocentric or immunocentric points of view will be presented...
  19. ncbi request reprint Cancer selective adenoviruses
    Ramon Alemany
    Virus Therapy Group, Translational Research Laboratory, Institut Catala d Oncologia, Barcelona, Spain
    Mol Aspects Med 28:42-58. 2007
    ..These challenges require a careful approach to clinical development and a great deal of collaboration to launch clinical tests with a virus backbone that contains intellectual property from multiple sources...
  20. ncbi request reprint Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting
    Neus Bayo-Puxan
    Translational Research Laboratory, IDIBELL Institut Català d Oncologia, Av Gran Via s n km 2 7, L Hospitalet de Llobregat, 08907 Barcelona, Spain
    J Gen Virol 87:2487-95. 2006
    ..The insertion of ligands at the hexon or protein IX may be required to benefit from the fiber shaft mutation-detargeting properties...
  21. doi request reprint Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency
    Alena Gros
    Translational Research Laboratory, IDIBELL Institut Català d Oncologia, L Hospitalet de Llobregat, Barcelona, Spain
    Cancer Res 68:8928-37. 2008
    ..Our results indicate that the inclusion of mutation 445A in tumor-selective adenoviruses would be a very powerful tool to enhance their antitumor efficacy...
  22. ncbi request reprint Adenovirus-mediated gene transfer to tumor cells
    Manel Cascallo
    Gene Therapy Program, Institut Catala d Oncologia, Barcelona, Spain
    Methods Mol Biol 246:121-38. 2004
    ..We present a radioactive labeling method that can be used to study biodistribution. After a small section dealing with tumor models, we describe methods to quantify different parameters related to adenovirus-mediated tumor targeting...
  23. doi request reprint Methods to construct recombinant adenovirus vectors
    Miguel Chillon
    Biochemistry and Molecular Biology Department, Laboratory of Gene Therapy for Autoimmune Diseases, CBATEG, Universitat Autonoma Barcelona, Barcelona, Spain
    Methods Mol Biol 737:117-38. 2011
    ..Finally, as a previous step before its amplification at medium or large scale, the viral pre-stock must be analyzed to quantify its potency and infectivity as well as to exclude the presence of unwanted replication competent particles...